Lilly Prices Olumiant For JAK Battle, But Misses Approval For Higher Dose
Lilly priced its now-approved Olumiant (baricitinib) to fight for US market share versus well-known rheumatoid arthritis therapies, undercutting Humira by 60% and Pfizer's established JAK inhibitor Xeljanz by 50%.
You may also be interested in...
The FDA approved baricitinib for the hair loss disorder despite safety concerns with JAK inhibitors. It carries the same warnings on risk of CV events and malignancy as the others in the class.
Lilly Bio-Medicines president Ilya Yuffa oversees newer products in competitive therapeutic areas and drug classes, but additional indications and new therapies within the group’s immunology, pain and neuroscience focus areas will capitalize on the group’s existing commercial expertise.
Access to branded drugs has remained steady, but there has been less management across brands by commercial payers, according to an analysis of the I&I market access environment by Bernstein.